PMID- 25803816
OWN - NLM
STAT- MEDLINE
DCOM- 20160225
LR  - 20200306
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 3
DP  - 2015
TI  - Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer 
      (IBC): prevalence, clinicopathologic features and prognostic implication.
PG  - e0120320
LID - 10.1371/journal.pone.0120320 [doi]
LID - e0120320
AB  - BACKGROUND: Inflammatory breast cancer (IBC) is the most aggressive form of 
      breast cancer, and its molecular pathogenesis still remains to be elucidated. 
      This study aimed to evaluate the prevalence and implication of anaplastic 
      lymphoma kinase (ALK) copy number change in IBC patients. METHODS: We 
      retrospectively collected formalin-fixed, paraffin-embedded tumor tissues and 
      medical records of IBC patients from several institutes in Korea. ALK gene copy 
      number change and rearrangement were assessed by fluorescence in situ 
      hybridization (FISH) assay, and ALK expression status was evaluated by 
      immunohistochemical (IHC) staining. RESULTS: Thirty-six IBC patients including 
      those with HER2 (+) breast cancer (16/36, 44.4%) and triple-negative breast 
      cancer (13/36, 36.1%) were enrolled in this study. ALK copy number gain (CNG) was 
      observed in 47.2% (17/36) of patients, including one patient who harbored ALK 
      gene amplification. ALK CNG (+) patients showed significantly worse overall 
      survival compared to ALK CNG (-) patients in univariate analysis (24.9 months vs. 
      38.1 months, p = 0.033). Recurrence free survival (RFS) after curative mastectomy 
      was also significantly shorter in ALK CNG (+) patients than in ALK CNG (-) 
      patients (n = 22, 12.7 months vs. 43.3 months, p = 0.016). Multivariate Cox 
      regression analysis with adjustment for HER2 and ER statuses showed significantly 
      poorer RFS for ALK CNG (+) patients (HR 5.63, 95% CI 1.11-28.44, p = 0.037). 
      CONCLUSION: This study shows a significant presence of ALK CNG in IBC patients, 
      and ALK CNG was associated with significantly poorer RFS.
FAU - Kim, Min Hwan
AU  - Kim MH
AD  - Division of Medical Oncology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Korea.
FAU - Lee, Soohyeon
AU  - Lee S
AD  - Division of Medical Oncology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Korea.
FAU - Koo, Ja Seung
AU  - Koo JS
AD  - Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
FAU - Jung, Kyung Hae
AU  - Jung KH
AD  - Department of Oncology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Korea.
FAU - Park, In Hae
AU  - Park IH
AD  - Center for Breast Cancer, National Cancer Center, Goyang, Korea; Department of 
      Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
FAU - Jeong, Joon
AU  - Jeong J
AD  - Department of Surgery, Gangnam Severance Hospital, Yonsei University College of 
      Medicine, Seoul, Korea.
FAU - Kim, Seung Il
AU  - Kim SI
AD  - Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
FAU - Park, Seho
AU  - Park S
AD  - Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
FAU - Park, Hyung Seok
AU  - Park HS
AD  - Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
FAU - Park, Byeong-Woo
AU  - Park BW
AD  - Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
FAU - Kim, Joo-Hang
AU  - Kim JH
AD  - Division of Medical Oncology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Korea.
FAU - Sohn, Joohyuk
AU  - Sohn J
AD  - Division of Medical Oncology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Korea.
LA  - eng
PT  - Clinical Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150324
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anaplastic Lymphoma Kinase
MH  - Breast/*pathology
MH  - Female
MH  - *Gene Amplification
MH  - *Gene Dosage
MH  - Humans
MH  - Inflammatory Breast Neoplasms/diagnosis/epidemiology/*genetics
MH  - Middle Aged
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Receptor Protein-Tyrosine Kinases/analysis/*genetics
MH  - Republic of Korea/epidemiology
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Triple Negative Breast Neoplasms/diagnosis/epidemiology/genetics
PMC - PMC4372579
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/03/25 06:00
MHDA- 2016/02/26 06:00
PMCR- 2015/03/24
CRDT- 2015/03/25 06:00
PHST- 2014/11/23 00:00 [received]
PHST- 2015/02/06 00:00 [accepted]
PHST- 2015/03/25 06:00 [entrez]
PHST- 2015/03/25 06:00 [pubmed]
PHST- 2016/02/26 06:00 [medline]
PHST- 2015/03/24 00:00 [pmc-release]
AID - PONE-D-14-51829 [pii]
AID - 10.1371/journal.pone.0120320 [doi]
PST - epublish
SO  - PLoS One. 2015 Mar 24;10(3):e0120320. doi: 10.1371/journal.pone.0120320. 
      eCollection 2015.